Retatrutide Weight Loss: Complete Triple Agonist Guide

## Imagine stepping on a scale 12 months from now and seeing a number 60 pounds lower than today. That is not a hypothetical -- it is what happened to average participants in the retatrutide Phase 2 trial. We do not make that statement lightly. Every new weight loss medication gets called "revolutionary" before the data comes in, and most fall short. We maintain a [complete comparison of all GLP-1 medications](/guides/glp1-medications-comparison-chart-guide) to help you see where each option ranks. But retatrutide (LY3437943) backed up the hype with numbers no obesity drug has matched: 24.2% average body weight reduction at the highest dose in just 48 weeks, published in the *New England Journal of Medicine* by Jastreboff et al. in 2023. Here is what you need to know about this triple agonist as of March 2026, based on published clinical evidence. ## What Makes Retatrutide Different from Other Weight Loss Medications? The answer is one word: glucagon. Every other major weight loss medication on the market works primarily by reducing how much you eat. Semaglutide and liraglutide activate GLP-1 receptors to suppress appetite. [Tirzepatide adds GIP receptor activation](/guides/tirzepatide-vs-semaglutide-comparison) for enhanced results. Retatrutide does all of that AND activates glucagon receptors, which increases how many calories your body burns at rest. It is the first medication to meaningfully address both sides of the energy balance equation: | Medication | What It Reduces | What It Burns | Max Weight Loss | |-----------|----------------|---------------|-----------------| | Semaglutide | Appetite (GLP-1) | -- | ~15-17% | | Tirzepatide | Appetite (GIP + GLP-1) | Minimal | ~20-22% | | **Retatrutide** | **Appetite (GIP + GLP-1)** | **Calories (Glucagon)** | **~24%** | That additional glucagon column is why retatrutide achieved more weight loss in less time than either competitor. ## The Three Mechanisms, Explained ### GLP-1 Activation You know this pathway if you have followed the semaglutide phenomenon. GLP-1 receptor activation slows gastric emptying, reduces hunger signals from your hypothalamus, and improves insulin sensitivity. The practical result: you feel full sooner, stay full longer, and stop thinking about food between meals. ### GIP Activation GIP (glucose-dependent insulinotropic polypeptide) amplifies the GLP-1 effect. When tirzepatide added GIP to GLP-1, it produced roughly 5-7 percentage points more weight loss than GLP-1 alone in the SURMOUNT-1 trial (Jepsen et al., NEJM 2022). GIP also enhances glucose-dependent insulin secretion and may protect pancreatic beta cells. ### Glucagon Activation -- The Differentiator This is where the science gets interesting. Glucagon receptor activation does three things other weight loss drugs cannot: 1. **Increases resting energy expenditure** -- your body burns more calories during normal daily activities, not just exercise 2. **Stimulates hepatic fat oxidation** -- your liver breaks down stored fat more aggressively 3. **Enhances thermogenesis** -- you produce more body heat, which requires caloric energy Published data from the Phase 2 trial showed measurable increases in metabolic rate among retatrutide participants that were not observed in the placebo group or in comparable semaglutide/tirzepatide trials. ## Phase 2 Trial Results: The Numbers The trial enrolled 338 adults with BMI 30+ (or 27+ with comorbidities). Here is what 48 weeks of treatment produced: ### Weight Loss by Dose - **1mg weekly:** ~8% body weight loss (initiation dose, sub-therapeutic) - **4mg weekly:** ~17% loss -- comparable to maximum-dose semaglutide - **8mg weekly:** ~22% loss -- comparable to maximum-dose tirzepatide - **12mg weekly:** ~24.2% loss -- the highest ever recorded in any obesity drug trial ### What 24% Loss Looks Like in Practice | Starting Weight | 24% Loss | New Weight | |----------------|----------|------------| | 200 lbs | 48 lbs | 152 lbs | | 250 lbs | 60 lbs | 190 lbs | | 300 lbs | 72 lbs | 228 lbs | | 350 lbs | 84 lbs | 266 lbs | Perhaps most striking: over 50% of participants on the 12mg dose lost 25% or more of their body weight, and the weight loss trajectory was still declining at week 48. Longer treatment may produce even greater results. ## How to Take Retatrutide: The Dosing Protocol Retatrutide is a once-weekly subcutaneous injection, similar to semaglutide and tirzepatide. The titration schedule from the clinical trial: **Weeks 1-4: 1mg** -- Adaptation phase. Minimal effects, minimal side effects. This is about letting your metabolism meet the triple mechanism gradually. **Weeks 5-8: 2mg** -- Appetite changes become noticeable. Many patients report eating 20-30% less without consciously restricting. **Weeks 9-12: 4mg** -- Therapeutic effects are clear. Significant appetite control, measurable weight loss. For some patients, this dose is sufficient long-term. **Weeks 13-16: 8mg** -- Enhanced metabolic effects from glucagon activation. Weight loss accelerates. Blood sugar improvements become pronounced. **Weeks 17+: 12mg (if needed)** -- Maximum dose. Not required for every patient -- many achieve excellent results at 4-8mg. **Our recommendation:** Do not rush the titration. Patients who try to skip doses or escalate faster than the protocol almost always experience worse GI side effects. The 4-week phases exist for a reason. ## Side Effects: An Honest Assessment The side effect profile is similar to other incretin therapies, with one addition: **Common GI effects:** Nausea (24-35%), diarrhea (15-25%), constipation (10-20%), vomiting (10-15%). These peak during dose escalation and typically resolve within 1-2 weeks at each new dose. Eating smaller meals, avoiding greasy foods, and injecting in the evening are the most effective management strategies. See our detailed [retatrutide side effects management guide](/guides/retatrutide-side-effects-management-guide) for specific protocols. **Heart rate (unique to retatrutide):** Glucagon activation causes a modest 5-10 bpm increase in resting heart rate. This was transient in most trial participants and did not lead to cardiac events. Patients with pre-existing heart conditions should discuss this with their cardiologist before starting. **Hair thinning:** A small percentage of patients report temporary hair thinning. This is related to the rapid weight loss itself (telogen effluvium), not the drug, and typically reverses after weight stabilizes. ## Who Is the Best Candidate for Retatrutide? Based on the trial population and clinical reasoning: - Adults with BMI 30+ who have not achieved goals with [semaglutide or tirzepatide](/guides/retatrutide-vs-semaglutide-comparison-guide) - Patients who plateaued on existing incretin therapy and need additional efficacy - Individuals with significant metabolic dysfunction (insulin resistance, fatty liver, metabolic syndrome) - Those whose healthcare provider has experience with peptide therapeutics **Not appropriate for:** Pregnant or nursing women, individuals with MTC/MEN2 family history, active pancreatitis, or anyone without medical supervision. ## How to Access Retatrutide: March 2026 Retatrutide is not FDA approved. Current options: 1. **Clinical trial enrollment** -- Eli Lilly Phase 3 trials may still be recruiting at select sites 2. **Compounding pharmacies** -- Available with a prescriber order from licensed 503A/503B pharmacies in the US 3. **Wait for approval** -- FDA review following Phase 3 completion, potentially 2026-2027 If using a [compounding pharmacy](/oem), verify it is US-based, state-licensed, and provides Certificates of Analysis for each batch. ## Getting Started 1. Find a healthcare provider experienced with incretin therapies 2. Get baseline labs: metabolic panel, A1C, lipid panel, thyroid function 3. Start at 1mg weekly and follow the [titration protocol](/guides/retatrutide-dosing-protocol-complete-titration-guide) faithfully 4. Track weight, measurements, and how you feel weekly 5. Aim for 100-150g daily protein to [preserve lean mass during weight loss](/guides/glp1-muscle-loss-prevention-semaglutide-tirzepatide-guide) 6. Stay hydrated (80+ ounces daily) and maintain 30 minutes of daily movement *Medical disclaimer: Retatrutide is investigational and not FDA approved. This article is for educational purposes only. Consult a qualified healthcare provider before making any treatment decisions.* --- ## References - [Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972). *New England Journal of Medicine*, 2023. - [Retatrutide once weekly for treatment of obesity: a phase 2 trial](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext). *The Lancet*, 2023. - [Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). *New England Journal of Medicine*, 2022. - [Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). *New England Journal of Medicine*, 2021. - [Glucagon receptor agonism enhances energy expenditure in obese subjects](https://pubmed.ncbi.nlm.nih.gov/?term=Glucagon+receptor+agonism+enhances+energy+expenditure). *Cell Metabolism*, 2023.